Iranian Journal of Diabetes and Obesity

en Comparison of Thrice-daily Novomix Insulin Versus Insulin Glargine Once-Daily Combined with Thrice-Daily Insulin Aspart on Glycemic Control in Patients with Type 2 Diabetes Mellitus: A Cross-Sectional Study تخصصي Special پژوهشي Research Objective: The objective of the present analysis was to compare the effect of these two treatment regimens (Novomix insulin twice or thrice-daily versus once-daily insulin glargine plus twice or thrice-daily insulin aspart) on glycemic control in Iranian patients with T2DM. Materials and Methods: This cross-sectional study was conducted for one year on people with type 2 diabetes referred to Yazd Medical Research Center. Glycemic control (HbA1C, FBG, and 2hPP) from baseline (week 0) to 24 -48 weeks were recorded in the electronic file of patients receiving Novomix insulin twice or thrice daily. These profiles were compared to those of patients receiving once-daily insulin glargine plus twice or thrice-daily insulin aspart (according to each meal). P< 0.05 was considered as a significant level. Results: Based on the finding, both treatment groups demonstrated significant reductions in FBG, 2hPP, and HbA1c from baseline to the study endpoint (weeks 24 and 48) (P< 0.05 for all comparisons). However, the changes in HbA1c, FBG, and 2hPP levels compared to the baseline level during the study were not significant between the two groups. Conclusion: The insulin glargine regime is effective in reducing HbA1C-FBS-2HPP compared to aspart and Novomix, but no significant difference was seen between the two mentioned regimes. It is recommended to observe more effectiveness and achieve more efficient and reliable results of the studies.   Insulin aspart, Insulin Glargine, Glycemic control, Diabetes mellitus, type 2. 149 153 http://ijdo.ssu.ac.ir/browse.php?a_code=A-10-30-418&slc_lang=en&sid=1 Seyyed Hossein Mirtorabi No MD,Shahid Sadoughi University of Medical Sciences, Yazd, Iran. Roghaye Razavi No Diabetes Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran. Roghaye Mirjalili No Diabetes Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran. Nasim Namiranian No Diabetes Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran. Mozhgan Modarresi No Assistant Professor of Community & Preventive Medicine, School of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran. Reyhaneh Azizi 0000-0003-2947-0076 Yes Assistant Professor of endocrinology, Yazd Diabetes Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.